GuidanceMar 29, 2026, 10:50 PM
AbbVie Lowers 2025 Adjusted EPS Guidance to $9.90-$9.94 Due to $1.3 Billion IPR&D Expense
AI Summary
AbbVie announced preliminary results for Q4 2025 and updated its full-year 2025 adjusted diluted earnings per share guidance to $9.90-$9.94, reflecting a $1.3 billion pre-tax acquired IPR&D and milestones expense. This expense will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.71.
Key Highlights
- Q4 2025 is expected to include $1.3 billion in acquired IPR&D and milestones expense.
- The expense will negatively impact GAAP and adjusted non-GAAP diluted EPS by $0.71.
- Full-year 2025 adjusted diluted EPS guidance is now $9.90 - $9.94, including the IPR&D expense.
- Q4 2025 adjusted diluted EPS guidance is $2.61 - $2.65, including the IPR&D expense.
Price Impact
More from ABBV
More in Guidance
RDZNApr 10, 8:51 AM
Roadzen Inc. Targets $100M Annualized Revenue Run Rate and Q2 2026 Adjusted EBITDA Breakeven, Driven by AI Deployment at Scale
ANGXApr 10, 7:31 AM
Angel Studios Projects Q1 2026 Revenue Between $105M-$109M, Anticipates Adjusted EBITDA Loss of $(4)M-$(6)M
LMRIApr 9, 5:16 PM
Lumexa Imaging Holdings Reaffirms Full Year 2026 Guidance During Investor Meeting